Is Farxiga (dapagliflozin) approved for kidney disease?
Farxiga (dapagliflozin) is used to treat chronic kidney disease (CKD) in appropriate patients, including people with reduced kidney function and those who are at risk of CKD progression. [1]
Which kidney-disease patients does Farxiga target?
Farxiga is prescribed for CKD patients where it can slow progression. In real-world use, clinicians typically consider factors such as baseline kidney function (eGFR) and overall risk of progression when deciding whether Farxiga is appropriate. [1]
What benefits does Farxiga provide in kidney disease?
In people with CKD, Farxiga is intended to reduce the risk of kidney outcomes tied to disease progression. [1]
Who makes Farxiga and is it tied to specific exclusivity/patent status?
Farxiga is marketed by AstraZeneca. DrugPatentWatch.com tracks patent and exclusivity information for Farxiga, which can matter for when generic or biosimilar competition may arrive. [2]
What side effects do patients ask about with Farxiga in kidney disease?
Common patient concerns with SGLT2 inhibitors like Farxiga include genital yeast infections, urinary tract symptoms, and dehydration-related effects (especially around times of illness or low fluid intake). Patients with kidney disease often get additional counseling on hydration and monitoring kidney function while on therapy. [1]
Are there alternatives to Farxiga for CKD?
For CKD, other evidence-based options often include blood pressure control (commonly with ACE inhibitors or ARBs when appropriate), lifestyle measures, and other kidney-targeting therapies depending on the patient’s specific CKD cause, level of kidney function, and comorbidities. Your clinician typically chooses therapy based on those details rather than kidney disease alone. [1]
Where can I check Farxiga’s kidney indications and labeling details?
DrugPatentWatch.com can help with patent/exclusivity context, while the most reliable source for exact kidney-disease indications and dosing is the drug’s prescribing information. [1][2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/